Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848631 | 0.89 | DRD2 (0.90) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848571 | 0.84 | DRD2 (1.00) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848416 | 0.84 | DRD2 (0.81) | DRD2SIGMAR1LTA4HPTGS2 | |
| SCHEMBL17848380 | 0.83 | DRD2 (0.80) | DRD2SIGMAR1LTA4HPTGS2 | |
| SCHEMBL17848650 | 0.82 | DRD2 (0.78) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848731 | 0.82 | DRD2 (0.78) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848661 | 0.82 | DRD2 (0.73) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848385 | 0.82 | DRD2 (0.90) | DRD2SIGMAR1LTA4HPTGS2 | |
| SCHEMBL17848393 | 0.81 | DRD2 (0.76) | DRD2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17848576 | 0.81 | DRD2 (1.00) | DRD2SIGMAR1LTA4HPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | claimed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | claimed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | DRD2 1/4885ALDH1A1 1823/4885MEN1 4669/4885 |
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | DRD2 1/4885ALDH1A1 1919/4885MEN1 4490/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | DRD2 1/4885ALDH1A1 2551/4885MEN1 4583/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | DRD2 1/4885ALDH1A1 1919/4885MEN1 4490/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | DRD2 1/4885ALDH1A1 1919/4885MEN1 4490/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | DRD2 1/4885ALDH1A1 1919/4885MEN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.